<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714801</url>
  </required_header>
  <id_info>
    <org_study_id>ASC Lungtransplantation</org_study_id>
    <nct_id>NCT04714801</nct_id>
  </id_info>
  <brief_title>Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation</brief_title>
  <official_title>A Danish, Single Centre, Double-blind, Randomized Study Evaluating Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy to Reduce Primary Graft Dysfunction After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety of treatment with allogeneic adipose tissue-derived mesenchymal stromal&#xD;
      cells (ASCs) in patients undergoing lung transplantation, to evaluate whether the treatment&#xD;
      can reduce host immunological reaction towards the graft, and to reduce the ischemic&#xD;
      reperfusion-injury after transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The emerging field of stem cell therapy holds promise of treating a variety of diseases.&#xD;
      Especially the mesenchymal stromal cells from bone marrow (BMSCs) or adipose tissue (ASCs)&#xD;
      have proven their potential for regenerative therapy in patients with ischemic heart disease.&#xD;
      Both of these cell types have putative immunomodulatory properties, as they have demonstrated&#xD;
      to actively suppress the immune system and hereby evade recognition.&#xD;
&#xD;
      This knowledge will be transferred into studies in the ischemic reperfusion-injury/primary&#xD;
      lung graft dysfunction in lung transplantation, and in suppressing the initial host&#xD;
      immunological response towards the transplanted lung where a high degree of immunological and&#xD;
      inflammatory activity is involved.&#xD;
&#xD;
      We will conduct a clinical trial in which patients receiving lung transplantation will be&#xD;
      randomized to either placebo or treatment with allogeneic MSCs from adipose tissue. The aim&#xD;
      is to assess the impact of MSCs on primary graft dysfunction.&#xD;
&#xD;
      The perspective is that this new information can be of pivotal importance and potentially be&#xD;
      a paradigm shift for the clinical problems seen in the first period after lung&#xD;
      transplantation and reduce the long-term graft rejection and dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind placebo-controlled dose titrating study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary graft dysfunction (PDG)</measure>
    <time_frame>3 days after treatment</time_frame>
    <description>Difference in presence or not presence of Primary graft dysfunction (PGD) after transplantation in ASC treated patients compared to controls.&#xD;
Primary graft dysfunction is defined, according to the International Society for Heart and Lung Transplantation (ISHLT), as presence of both pulmonary infiltrates and hypoxemia occurring within the first 72 hours after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney glomerular Filtration Rate</measure>
    <time_frame>12 weeks after treatment</time_frame>
    <description>Difference in estimated Glomerular Filtration Rate (eGFR)/1,73 m2. Normal &gt; 60 ml/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>through the 12 weeks</time_frame>
    <description>Differences in C-reactive protein. Normal value &lt; 10mg/ml</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Infusion of 100 million ASC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infusion of 200 million ASC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infusion of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adipose derived mesenchymal stromal cells</intervention_name>
    <description>Intravenous infusion of cells</description>
    <arm_group_label>Infusion of 100 million ASC</arm_group_label>
    <arm_group_label>Infusion of 200 million ASC</arm_group_label>
    <other_name>CSCC_ASC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous infusion of saline</description>
    <arm_group_label>Infusion of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female lung recipients 18-70 years of age undergoing primary double (including&#xD;
             size reduction) lung transplantation.&#xD;
&#xD;
          -  Patient willing and capable of giving written informed consent for study participation&#xD;
             and anticipated to be able to participate in the study for 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipients of multi-organ transplant, and or previously transplanted with any solid&#xD;
             organ, including previous lung transplantation.&#xD;
&#xD;
          -  Patients scheduled for single lung transplantation.&#xD;
&#xD;
          -  Patients in need of acute transplantation e.g. patients on urgent call for&#xD;
             transplantation and patients on respirator or on extra corporal membrane oxygenation&#xD;
             (ECMO) treatment at time of transplantation.&#xD;
&#xD;
          -  Patients that based on crossmatch prior to transplantation have need for additional&#xD;
             immunosuppressive treatment&#xD;
&#xD;
          -  Donor lung cold ischemic time &gt; 12 hours.&#xD;
&#xD;
          -  Patients with platelet count &lt; 50,000/mm3 at the evaluation before transplantation.&#xD;
&#xD;
          -  Patients who are unlikely to comply with the study requirements.&#xD;
&#xD;
          -  Patient unable to participate in the study for the full study period&#xD;
&#xD;
          -  Patients with any past (within the past 3-5 years) or present malignancy (other than&#xD;
             excised basal cell carcinoma).&#xD;
&#xD;
          -  Females capable of becoming pregnant must have a negative pregnancy test prior to&#xD;
             transplantation. After inclusion, they must use contraceptives for 2 months following&#xD;
             the given stem cell treatment. The pill, spiral, depot injection of progesterone,&#xD;
             sub-dermal implantation, hormonal vaginal ring and transdermal patch regarded as safe&#xD;
             contraceptives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kastrup, MD Professor</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Perch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Kastrup, MD Professor</last_name>
    <phone>+4535452819</phone>
    <email>jens.kastrup@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abbas A Qayuum, MD</last_name>
    <phone>+4535452819</phone>
    <email>Abbas.Ali.Qayyum@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Kastrup, MD DMSc</last_name>
      <phone>+4535452817</phone>
      <email>jens.kastrup@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jens Kastrup, MD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>JKastrup</investigator_full_name>
    <investigator_title>MD professor</investigator_title>
  </responsible_party>
  <keyword>lung transplantation</keyword>
  <keyword>Rejection</keyword>
  <keyword>mesenchymal stromal cell</keyword>
  <keyword>immune modulation</keyword>
  <keyword>clinical trial</keyword>
  <keyword>treatment</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We are open for collaboration with external research groups, but have no presently plans</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>When the study is finalized and published</ipd_time_frame>
    <ipd_access_criteria>Relevant documented use of data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

